Literature DB >> 10637448

Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.

C H Chen1, H Ji, K W Suh, M A Choti, D M Pardoll, T C Wu.   

Abstract

DNA vaccination has emerged as an attractive approach for tumor immunotherapy. The aim of this study was to evaluate the potency of DNA vaccines in preventing and treating the liver and lung metastases of a human papillomavirus-16 (HPV-16) E7-expressing murine tumor (TC-1). We used the gene gun method to vaccinate C57BL/6 mice intradermally with DNA vaccines containing the HPV-16 E7 gene, the E7 gene linked to the sorting signals of the lysosome-associated membrane protein-1 (Sig/E7/ LAMP-1), or the 'empty' plasmid vector. The in vivo antitumor immunity was analyzed in both tumor prevention and tumor regression experiments. In addition, cytotoxic T lymphocyte (CTL) assays, enzyme-linked immunospot assay and enzyme-linked immunoabsorbent assay were used to assess the E7-specific T cell-mediated and humoral immunity. Mice vaccinated with Sig/E7/LAMP-1 DNA generated the strongest E7-specific CTL activities, the highest numbers of E7-specific CD8+ cell precursors and the highest titers of E7-specific antibodies. While both E7 DNA and Sig/E7/LAMP-1 DNA generated potent antitumor immunity in the liver and lung metastases models, the Sig/E7/LAMP-1 DNA was more potent under stringent conditions. DNA vaccination with E7-expressing plasmids was effective in controlling liver and lung metastases of an E7-expressing murine tumor. Our data suggest that antigen-specific DNA vaccination can potentially be applied to control liver and lung metastases of tumors with defined tumor-specific antigens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10637448     DOI: 10.1038/sj.gt.3301067

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

Review 1.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

2.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

3.  Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

Authors:  Yi-Hsin Lin; Ming-Chieh Yang; Ssu-Hsueh Tseng; Rosie Jiang; Andrew Yang; Emily Farmer; Shiwen Peng; Talia Henkle; Yung-Nien Chang; Chien-Fu Hung; T-C Wu
Journal:  Cancer Immunol Res       Date:  2018-01-23       Impact factor: 11.151

4.  Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.

Authors:  Mi Suk Kim; Jeong-Im Sin
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

5.  Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.

Authors:  Vitaly Vasilevko; Anahit Ghochikyan; Nadya Sadzikava; Irina Petrushina; Mike Tran; Edward P Cohen; Patrick J Kesslak; David H Cribbs; Garth L Nicolson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency.

Authors:  Bruce Huang; Chih-Ping Mao; Shiwen Peng; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

7.  Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases.

Authors:  Mika Kamata; Kaori Denda-Nagai; Nobuyoshi Kubota; Satoshi Aida; Kazuyoshi Takeda; Tatsuro Irimura
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

8.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

9.  Lysine: Is it worth more?

Authors:  D Datta; A Bhinge; V Chandran
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

Review 10.  A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing.

Authors:  Apresio K Fajrial; Qing Qing He; Nurul I Wirusanti; Jill E Slansky; Xiaoyun Ding
Journal:  Theranostics       Date:  2020-04-15       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.